IL6 and myeloid sarcoma: Therefore, the aim of this study was to extend serum profiles of cytokines, chemokines and related molecules in patients with MOGAD or AQP4+ NMOSD, with a particular focus on IL-6, to better understand underlying disease pathophysiology and find potential biomarkers to distinguish those antibody-mediated conditions from MS.